Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities:
Net income (loss)	$ 2,635	$ (3,160)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation expense	2,511	3,375
Depreciation and amortization	551	689
Amortization of debt discount	158	88
Amortization of debt issuance costs	53	52
Accretion of discount on short-term investments	(281)	(638)
Retirement and impairment of property and equipment		170
Gain on disposal of property and equipment	(34)
Change in operating assets and liabilities:
Accounts receivable	145	(5,185)
Inventory	(3,772)	(363)
Prepaid expenses and other assets	(8,604)	(222)
Accounts payable	624	(2,403)
Accrued clinical and manufacturing liabilities	(5,466)	(2,347)
Accrued payroll and employee-related liabilities	(3,103)	(1,577)
Other accrued expenses	5,713	2,005
Net cash used in operating activities	(8,870)	(9,516)
Investing activities:
Purchases of short-term investments	(22,902)	(37,892)
Maturities and sales of short-term investments	25,242	39,170
Purchases of property and equipment	(109)
Proceeds from the sale of property and equipment	42
Net cash provided by investing activities	2,273	1,278
Financing activities:
Receipts for stock issued under the equity incentive plan	64	11
Net cash provided by financing activities	64	11
Net decrease in cash and cash equivalents	(6,533)	(8,227)
Cash and cash equivalents at beginning of period	25,802	28,677
Cash and cash equivalents at end of period	19,269	20,450
Supplemental disclosure of cash flow information:
Interest paid	$ 636	$ 649